Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry.
Crespo-Leiro MG, Alonso-Pulpón L, Arizón JM, Almenar L, Delgado JF, Palomo J, Manito N, Rábago G, Lage E, Diaz B, Roig E, Pascual D, Blasco T, de la Fuente L, Campreciós M, Vázquez de Prada JA, Muñiz J. Crespo-Leiro MG, et al. Among authors: roig e. J Heart Lung Transplant. 2007 Nov;26(11):1105-9. doi: 10.1016/j.healun.2007.08.010. J Heart Lung Transplant. 2007. PMID: 18022075
The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation.
Delgado JF, Manito N, Segovia J, Almenar L, Arizón JM, Campreciós M, Crespo-Leiro MG, Díaz B, González-Vílchez F, Mirabet S, Palomo J, Roig E, de la Torre JM. Delgado JF, et al. Among authors: roig e. Transplant Rev (Orlando). 2009 Apr;23(2):69-79. doi: 10.1016/j.trre.2009.01.002. Transplant Rev (Orlando). 2009. PMID: 19298938 Review.
Prevalence and severity of renal dysfunction among 1062 heart transplant patients according to criteria based on serum creatinine and estimated glomerular filtration rate: results from the CAPRI study.
Crespo-Leiro MG, Delgado JF, Paniagua MJ, Vázquez de Prada JA, Fernandez-Yañez J, Almenar L, Diaz-Molina B, Roig E, Arizón JM, Alonso-Pulpón L, Garrido IP, Sanz ML, de la Fuente L, Mirabet S, Manito N, Muñiz J. Crespo-Leiro MG, et al. Among authors: roig e. Clin Transplant. 2010 Jul-Aug;24(4):E88-93. doi: 10.1111/j.1399-0012.2009.01178.x. Clin Transplant. 2010. PMID: 20030676
Risk factors associated with moderate-to-severe renal dysfunction among heart transplant patients: results from the CAPRI study.
Delgado JF, Crespo-Leiro MG, Gómez-Sánchez MA, Paniagua MJ, González-Vílchez F, Vázquez de Prada JA, Fernández-Yáñez J, Pascual D, Almenar L, Martínez-Dolz L, Díaz B, Roig E, Segovia J, Arizón JM, Garrido I, Blasco T, López J, Brossa V, Manito N, Muñiz J. Delgado JF, et al. Among authors: roig e. Clin Transplant. 2010 Sep-Oct;24(5):E194-200. doi: 10.1111/j.1399-0012.2010.01249.x. Clin Transplant. 2010. PMID: 20597926
Clinical recommendations for the use of everolimus in heart transplantation.
Manito N, Delgado JF, Crespo-Leiro MG, González-Vílchez F, Almenar L, Arizón JM, Díaz B, Fernández-Yáñez J, Mirabet S, Palomo J, Rodríguez Lambert JL, Roig E, Segovia J. Manito N, et al. Among authors: roig e. Transplant Rev (Orlando). 2010 Jul;24(3):129-42. doi: 10.1016/j.trre.2010.01.005. Transplant Rev (Orlando). 2010. PMID: 20619801 Review.
Report from a consensus conference on antibody-mediated rejection in heart transplantation.
Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, Burke M, Czer L, Hiemann N, Kfoury AG, Mancini D, Mohacsi P, Patel J, Pereira N, Platt JL, Reed EF, Reinsmoen N, Rodriguez ER, Rose ML, Russell SD, Starling R, Suciu-Foca N, Tallaj J, Taylor DO, Van Bakel A, West L, Zeevi A, Zuckermann A; Consensus Conference Participants. Kobashigawa J, et al. J Heart Lung Transplant. 2011 Mar;30(3):252-69. doi: 10.1016/j.healun.2010.11.003. J Heart Lung Transplant. 2011. PMID: 21300295 Free PMC article.
Withdrawal of proliferation signal inhibitors due to adverse events in the maintenance phase of heart transplantation.
Gonzalez-Vilchez F, Vazquez de Prada JA, Almenar L, Arizon Del Prado JM, Mirabet S, Diaz-Molina B, Delgado JF, Gomez-Bueno M, Paniagua MJ, Perez-Villa F, Roig E, Martínez-Dolz L, Brossa V, Lambert JL, Segovia J, Crespo-Leiro MG, Ruiz-Cano MJ. Gonzalez-Vilchez F, et al. Among authors: roig e. J Heart Lung Transplant. 2012 Mar;31(3):288-95. doi: 10.1016/j.healun.2011.10.011. Epub 2011 Dec 1. J Heart Lung Transplant. 2012. PMID: 22133787
Rejection after conversion to a proliferation signal inhibitor in chronic heart transplantation.
González-Vílchez F, Vázquez de Prada JA, Paniagua MJ, Almenar L, Mirabet S, Gómez-Bueno M, Díaz-Molina B, Arizón JM, Delgado J, Pérez-Villa F, Crespo-Leiro MG, Martínez-Dolz L, Roig E, Segovia J, Lambert JL, Lopez-Granados A, Escribano P, Farrero M. González-Vílchez F, et al. Among authors: roig e. Clin Transplant. 2013 Nov-Dec;27(6):E649-58. doi: 10.1111/ctr.12241. Epub 2013 Sep 12. Clin Transplant. 2013. PMID: 24025040
203 results